Approaches to therapy of prion diseases. Export

@article{citeulike:2841615, abstract = {Devising approaches to the therapy of transmissible spongiform encephalopathies, or prion diseases, is beset by many difficulties. For one, the nature of the infectious agent, the prion, is understood only in outline, and its composition, structure, and mode of replication are still shrouded in mystery. In addition, the mechanism of pathogenesis is not well understood. Because clinical disease affects mainly the brain parenchyme, therapeutic agents must be able to traverse the brain-blood barrier (BBB) or have to be introduced directly into the cerebrospinal fluid or brain tissue. And finally, because the disease is usually recognized only after onset of severe clinical symptoms, the question arises as to whether the neurodegenerative processes can be reversed to any extent after a successful eradication of the agent.}, address = {Department of Neurodegenerative Disease/MRC Prion Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK. charles.weissmann@prion.ucl.ac.uk}, author = {Weissmann, C. and Aguzzi, A.}, citeulike-article-id = {2841615}, citeulike-linkout-0 = {http://dx.doi.org/10.1146/annurev.med.56.062404.172936}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15660515}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15660515}, doi = {10.1146/annurev.med.56.062404.172936}, issn = {0066-4219}, journal = {Annual review of medicine}, keywords = {prion, therapy, treatment}, pages = {321--344}, posted-at = {2008-11-14 09:32:45}, priority = {2}, title = {Approaches to therapy of prion diseases.}, url = {http://dx.doi.org/10.1146/annurev.med.56.062404.172936}, volume = {56}, year = {2005} }

TY - JOUR ID - citeulike:2841615 L3 - citeulike-article-id:2841615 N2 - Devising approaches to the therapy of transmissible spongiform encephalopathies, or prion diseases, is beset by many difficulties. For one, the nature of the infectious agent, the prion, is understood only in outline, and its composition, structure, and mode of replication are still shrouded in mystery. In addition, the mechanism of pathogenesis is not well understood. Because clinical disease affects mainly the brain parenchyme, therapeutic agents must be able to traverse the brain-blood barrier (BBB) or have to be introduced directly into the cerebrospinal fluid or brain tissue. And finally, because the disease is usually recognized only after onset of severe clinical symptoms, the question arises as to whether the neurodegenerative processes can be reversed to any extent after a successful eradication of the agent. JF - Annual review of medicine SN - 0066-4219 AD - Department of Neurodegenerative Disease/MRC Prion Unit, Institute of Neurology, Queen Square, London WC1N 3BG, UK. charles.weissmann@prion.ucl.ac.uk EP - 344 TI - Approaches to therapy of prion diseases. VL - 56 SP - 321 KW - prion KW - therapy KW - treatment AU - Weissmann, C AU - Aguzzi, A PY - 2005/// UR - http://dx.doi.org/10.1146/annurev.med.56.062404.172936 ER -